CS logo
small CS logo
Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica

Arequipa, Peru
Hospital in Arequipa
INREN, Av. La Salud S/N- Cercado, Arequipa 04002

About Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender

Clinical Trials at Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica


During the past decade, Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Clinical Trials Sponsors and Collaborators



Clinical Trials Conditions at Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica


According to Clinical.Site data, the most researched conditions in "Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica" are "Carcinoma, Non-Small-Cell Lung" (2 trials), "Breast Cancer" (1 trials), "Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With" (1 trials), "Glucocorticoid-induced Osteoporosis" (1 trials) and "Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica" in a lesser frequency.

Clinical Trials Intervention Types at Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica


Most popular intervention types in "Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (2 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Bevacizumab" (1 trials), "Carboplatin" (1 trials) and "Denosumab" (1 trials). Other intervention names were less common.

Clinical Trials Genders at Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica


The vast majority of trials in "Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica" are 4 trials for "All" genders and 1 trials for "Female" genders.

Clinical Trials Status at Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica


Currently, there are NaN active trials in "Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica, undefined suspended trials, and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".